Strides Pharma Science Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
For the six months, sales was INR 19,294.21 million compared to INR 18,371.71 million a year ago. Revenue was INR 19,739.14 million compared to INR 18,741.78 million a year ago. Net loss was INR 1,384.56 million compared to INR 1,130.67 million a year ago. Basic loss per share from continuing operations was INR 15.33. Diluted loss per share from continuing operations was INR 15.33. Basic loss per share was INR 15.33 compared to INR 12.58 a year ago. Diluted loss per share was INR 15.33 compared to INR 12.58 a year ago.